A Clearinghouse for Information about Blood Clots (DVT/)PE) and Clotting Disorders (thrombophilia) provided as a public service by the University of North Carolina Blood Research Center

Tag: warfarin

  • Coumadin®: Discontinuation of Sale

    Dr. Stephan Moll and Beth Waldron write (last updated April 28, 2020): The company making Coumadin® (warfarin sodium) tablets, Bristol-Myers Squibb (BMS), announced that it will discontinue the sale and distribution of Coumadin® (see the FDA filing here). A memo on the BMS website says: “all strengths of Coumadin® (warfarin sodium) tablets will be discontinued…

  • Coronavirus for patients: Plan your blood thinner medication refills

    Beth Waldron, MA writes….For patients on life-saving therapies like blood thinners (anticoagulants) having several weeks supply of medication on hand during the coronavirus outbreak is important not only to reduce the need to be out in public, but to ensure you have everything you need already at home if you do get sick. However, getting…

  • Antiphospholipid Syndrome: Can the New Oral Anticoagulants Be Used?

    Stephan Moll, MD and Damon Houghton, MD write … In patients with antiphospholipid syndrome (APS) who require anticoagulation for the treatment of DVT or PE, warfarin or a low molecular weight heparin have traditionally been used. A question that comes up is whether one of the new oral anticoagulants (DOACs) can be effectively and safely…

  • Heavier Menstrual Bleeding on Xarelto?

    Stephan Moll, MD writes… Interesting and noteworthy observations published in the last 2 weeks:  Heavy menstrual bleeding appears to occur more commonly with Xarelto® than with warfarin [ref 1] and may be also more common with Xarelto® than with Eliquis® [ref 2].

  • Reversing Warfarin for Urgent Surgeries – Extended FDA Approval of Kcentra

    Stephan Moll, MD writes… The FDA approved today (Dec 13th, 2013) the use of the drug Kcentra® for urgent warfarin reversal in patients who need an urgent surgical procedure.  This extends the indications for use of this drug – it had been approved by the FDA in April 2013 to treat major bleeding on warfarin…

  • Major Bleeding on Dabigatran (Pradaxa) – Interesting Publication

    Stephan Moll, MD writes… Interesting publication this week in Circulation: “Management and outcomes of major bleeding during treatment with dabigatran or warfarin” (Majeed A et al; published online Sept 30,2013;  full publication is here).  The management and prognosis of major bleeding in patients treated with dabigatran or warfarin was compared, pooling data of the major bleeds that occurred in 5 phase III…

  • International Coagulation Meeting (ISTH 2013): Highlights

    Stephan Moll, MD writes…  A major international coagulation conference, the bi-annual meeting of the International Society for Thrombosis and Haemostasis (ISTH; http://www.isth.org), took place in Amsterdam, Holland, from June 29th to July 4th, 2013.  The clinically relevant highlights about thrombosis and anticoagulation are summarized below.

  • FDA Approval of New Drug to Treat Major Bleeding on Warfarin – Kcentra

    Stephan Moll, MD writes…  A new drug for the urgent reversal of warfarin was approved by the FDA today, April 29th, 2013 (announcement by the FDA is here), called Kcentra.  The drug is derived from pooled plasma from healthy blood donors and contains the coagulation factors that are low in warfarin-treated patients, i.e. factors II, VII,…